Hing (Asafoetida) for Anti-Inflammatory

Research suggests that asafoetida demonstrates consistent anti-inflammatory activity across a range of preclinical study designs, including in vivo rodent models using standard inflammation assays such as carrageenan-induced paw edema, in vitro cell-based studies in human vascular endothelial cells, and mechanistic investigations into specific chemical constituents such as sesquiterpene coumarins and hydroxycinnamic acids. Studies indicate the plant resin reduces pro-inflammatory markers including TNF-α, TGF-β, ICAM-1, VCAM-1, and E-selectin, and appears to act through multiple pathways including lipoxygenase inhibition and the cGAS-STING signaling axis, with additional evidence from disease-specific models such as ulcerative colitis, diabetic nephropathy, and diabetic neuropathy. A 2011 narrative review and a 2025 review both corroborate these findings by summarizing the broader body of traditional use and laboratory evidence. However, all available evidence comes from animal studies, cell culture experiments, and reviews of such work — no human clinical trials have been identified in this body of research, which is a significant limitation when considering how these findings might translate to real-world use in people.